Ebstein anomaly (EA) is a rare congenital tricuspid valve malformation, characterized by downward displacement of the septal leaflet and an atrialized right ventricle. About 80% of cases of EA are non-syndromic; in the other 20%, the anomaly is associated with a chromosomal or Mendelian syndrome. The prevalence of EA is estimated at about 1 per 20,000 live births, and accounts for less than 1% of all congenital heart defects. EA has autosomal dominant inheritance. Likely causative genes are: NKX2-5, MYH7 and TPM1. This Utility Gene Test was developed on the basis of an analysis of the literature and existing diagnostic protocols. It is useful for confirming diagnosis, as well as for differential diagnosis, potential risk assessment and access to clinical trials.
The diagnostic work-up includes clinical assessment to identify symptoms, echocardiogram, electrocardiogram, chest radiogram, integration of septal and color Doppler with two-dimensional echocardiography, spin-echo MR imaging, CT, diagnostic catheterization and genetic testing.
Differential diagnosis should consider EA caused by Down syndrome and other chromosomal disorders.
Non-syndromic EA has autosomal dominant inheritance with variable expressivity and incomplete penetrance.
Candidate genes for EA (OMIM disease 224700)
• NKX2-5 (OMIM gene 600584) (10) • MYH7 (OMIM gene 160760) (10) • TPM1 (OMIM gene 191010) (13) In humans, mutations in the NKX2-5 gene provided the first evidence that genetic factors are etiologically crucial in non-syndromic congenital heart diseases (14) . The most common phenotypes are secundum atrial septal defect and atrioventricular conduction disturbance, but cases of EA are also reported (15, 16) .
MYH7 mutations are predominantly found in EA associated with left ventricular non-compaction cardiomyopathy (LVNC) (17); a convincing hypothesis regarding this association is that LVNC is the result of altered cell regulation during wall formation (18) and EA may be caused by an arrest in directional growth during this process (19, 20) .
TPM1 encodes α-tropomyosin, which is involved in myocardial contraction, as well as in stabilization of nonmuscle cytoskeletal actin filaments. Nijak et al. reported an LVNC-EA family with a TPM1 mutation, and established an association between EA and TPM1-related LVNC (21) .
Pathogenic variants may include missense and nonsense mutations and small deletions.
Aims of the test
• To determine the gene defect responsible for the disease;
• To confirm clinical diagnosis;
• To assess the recurrence risk and perform genetic counselling for at-risk/affected individuals.
Test characteristics

Specialist centers/ Published Guidelines
The test is listed in the Orphanet database and is offered by 2 accredited medical genetic laboratories in the EU, and in the GTR database, offered by 11 accredited medical genetic laboratories in the US. Guidelines for clinical use of the test are described in Genetics Home Reference (ghr.nlm.nih.gov).
Test strategy
A multi-gene next generation sequencing panel is used for the detection of nucleotide variations in coding exons and flanking introns of the above genes.
Potentially causative variants and regions with low cover-age are Sanger-sequenced. Sanger sequencing is also used for family segregation studies. To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml peripheral blood in a sterile tube with 0.5 ml K 3 EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated.
Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance.
Genetic test results
Positive
Identification of pathogenic variants in the above genes confirms the clinical diagnosis and is an indication for family studies.
A pathogenic variant is known to be causative for a given genetic disorder based on previous reports, or predicted to be causative based on loss of protein function or expected significant damage to proteins or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.
Inconclusive
Detection of a variant of unknown or uncertain significance (VUS): a new variation without any evident pathogenic significance or a known variation with insufficient evidence (or with conflicting evidence) to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives to assess variant segregation and clarify its contribution. In some cases, it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.
Negative
The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:
• alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments; • sequence variations in gene regions not investigated by this test, such as regulatory regions (5' and 3' UTR) and deep intronic regions; • variations in other genes not investigated by the present test.
Unexpected
Unexpected results may emerge from the test, for example information regarding consanguinity, absence of family correlation or other genetically-based diseases.
Risk for progeny
In autosomal dominant transmission, the probability that an affected carrier transmit the variant to his/her children is 50% in any pregnancy, irrespective of the sex of the child conceived.
Limits of the test
The test is limited by current scientific knowledge regarding the gene and disease.
Analytical sensitivity (proportion of positive tests when the genotype is truly present) and specificity (proportion of negative tests when the genotype is not present) Clinical sensitivity: variations in the aforementioned genes are linked to EA, but may be individual variations (identified in one or a few families) and total epidemiological data is therefore not available.
Clinical sensitivity will be estimated based on internal cases.
Clinical specificity: data not available.
Prescription appropriateness
The genetic test is appropriate when: a) the patient meets the diagnostic criteria for EA; b) the sensitivity of the test is greater than or equal to that of tests described in the literature.
Clinical utility
Clinical management Utility
Confirmation of clinical diagnosis Yes
Differential diagnosis Yes
Couple risk assessment Yes
Availability of clinical trials can be checked on-line at https://clinicaltrials.gov/
